Maxim Group下调评级CNS Pharmaceuticals评级为持有

同花顺iNews
26 Mar

同花顺美股讯 3月25日Maxim Group将cns pharmaceuticals评级从买入下调评级为持有。CNS Pharmaceuticals于11月14日发布2024年三季报,公司截至2024年9月30日,净利润-1168.14万美元,基本每股收益-1.54美元。CNS Pharmaceuticals, Inc.是一家临床制药公司,于2017年7月27日作为内华达州公司组建,专注于开发...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10